Tracer library / [161Tb]Tb-DOTATATE

Structure of DOTATATE (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 11170867

[161Tb]Tb-DOTATATE

Also written as DOTATATE; [Tb-161]Tb-DOTATATE; DOTA-TATE; dotatate

Radionuclide: Tb-161 t½ 9907.2 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 3

Neuroendocrine neoplasms Preclinical only, no clinical indication yet Peptide receptor radionuclide therapy Neuroblastoma (paediatric)

What it is

Compound class: DOTATATE somatostatin analogue (radiolabelled peptide)
Target / mechanism: Somatostatin receptor 2 (SSTR2) agonist PMID 42518020
Clinical application: Peptide receptor radionuclide therapy of somatostatin receptor-expressing neuroendocrine neoplasms and neuroblastoma PMID 42518020
Theranostic pair: [68Ga]Ga-DOTATATE

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	>97%	>90%	DOTATATE Bachem, Bubendorf, Switzerland	42518020 2026 EJNMMI Res Radiolabelling was performed by mixing DOTATATE (1.5 ug; 1 mg/mL in metal free water) (Bachem, Bubendorf, Switzerland) with approximately 60 MBq of non-carrier added [161Tb]TbCl3 - The reaction consistently produced a high radiochemical yield, averaging > 97%.
Manual synthesis	—	none	—	>98%	DOTATATE Bachem, Bubendorf, Switzerland	39046521 2024 Eur J Nucl Med Mol Imaging DOTA-LM3 (CSBio, Silicon Valley Menlo Park, California, United States) and DOTATATE (Bachem, Bubendorf, Switzerland) were labeled with terbium-161 or lutetium-177 at a molar activity of up to 100 MBq/nmol using standard labeling conditions as previously reported
Manual synthesis n/a	—	—	>99%	>99%	DOTATATE	42411199 2026 Nucl Med Commun [161Tb]Tb-DOTATATE was prepared by reconstituting DOTATATE in sodium acetate buffer (pH 4.5), along with ascorbic acid as a radio-stabilizer. - the radiolabeling yield, which was greater than 99% at 1 h

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Bachem, Bubendorf
Typical final purification: —

Need this precursor?We can point you to suppliers for [161Tb]Tb-DOTATATE, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64, Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 42518020: 'DOTATATE (1.5 ug; 1 mg/mL in metal free water) (Bachem, Bubendorf, Switzerland)'. | Stage 28: added indication(s) onc-neuroblastoma from consolidated missing-rubric review. Stage set/updated at stage 39 from PMID 42518020: '[161Tb]Tb-DOTATATE demonstrates favourable targeting properties and activity-dependent therapeutic efficacy in preclinical neuroblastoma models without detectable toxicity.'.